LoQus23 Therapeutics

Healthcare & Life Sciences

Recent Finacing

Series A

Recent Raise

$46.5M

LoQus23 Therapeutics develops small molecule drugs to halt DNA instability and slow neurodegeneration in triplet repeat diseases like Huntington's disease.

Total Funding

$46.5M

Headquarters

Cambridge, United Kingdom

Founded

2019

Website

loqus23.com

Focus Areas

biotech

small molecule drugs

DNA instability

neurodegeneration

triplet repeat diseases

Huntington's disease

Investors